Hypervascular Tumors clinical trials at UCLA
1 in progress, 0 open to eligible people
Showing trials for
Obsidio™ Conformable Embolic Registry
Sorry, not currently recruiting here
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects …
Los Angeles, California and other locations
Our lead scientists for Hypervascular Tumors research studies include Zachary Haber, MD.
Last updated: